LUMYNA Pharma — Commercialization, reimagined.
We turn life sciences |innovation| into |access|, |growth| and |impact|.
Biotech innovation is accelerating. Access is not. Markets are fragmented. Commercial pathways are complex. And too many innovative therapies never reach the patients who need them.
Market access is not the final step of commercialization. It starts much earlier.
European growth rarely follows a straight line. We help innovative companies navigate fragmented markets, identify the right partners and build scalable expansion strategies.
LUMYNA brings clarity to that complexity. We advise. We build. We execute. From science to market. From market to patients.
Across Europe, |fragmentation| turns innovation into |cost|, |risk| and |delay|.
30+ national markets, healthcare and reimbursement environments. Europe is not one market. It is a collection of healthcare systems, reimbursement environments, stakeholder ecosystems and commercial realities. Innovation is not the problem. The gap between approval and access is. See how early access programs and market access close it.
€150M+ of potential value can be at risk when European commercialization is delayed or under-executed. Selected market indicators; figures vary by asset, therapeutic area and market.
Up to 80% of European orphan drug launches may fail to meet commercial and revenue goals and reach patients in need. The “up to 80%” orphan drug figure is a widely cited industry estimate.
18–36 months can be lost through delayed market entry and fragmented commercialization.
LUMYNA sits at the intersection of |strategy|, |access|, |commercialization| and |growth|.
A boutique life sciences commercialization and advisory platform. We work with biotech, pharma, medtech and healthcare innovators as strategic advisors, commercial partners or hands-on operators.
No access. No impact.
We don’t believe in the distance between consulting and execution. We believe in what happens after the strategy. That is where we add value. We don’t stop at strategy.
One market can become a platform for growth.
We |think|, we |build|, we |scale|.
Understand the opportunity. Market intelligence. Commercial assessment. Competitive landscape. Asset evaluation. Commercial strategy.
Create the pathway. Market access. Pricing and reimbursement. Partnering. Market entry. Launch strategy.
Turn momentum into growth. Commercial operations. Market expansion. Business development. Licensing. Commercial excellence. From insight to execution. From execution to impact.
One integrated platform: |advisory|, |access|, |commercialization| and |growth|.
Clarity before action. The best commercial decisions start with understanding what actually matters. Commercial strategy. Market and opportunity assessment. Commercial due diligence. Asset evaluation. Portfolio strategy. Go-to-market strategy. Organizational design. Interim and fractional leadership.
From value proposition to patient access. Market access strategy. Pricing and reimbursement. HTA. Value proposition. Stakeholder engagement. Early access. Patient access models.
From approval to adoption. Regulatory approval opens the door. Commercial execution gets you through it. Launch strategy. Commercial operations. Sales and marketing. Market development. Medical affairs support. Distribution models. Commercial excellence. Performance management. We don’t just launch products. We build markets.
Beyond the first market. International expansion. Business development. Licensing. Partnering. Alliance management. Market entry. Portfolio expansion. Growth strategy.
|Senior| by default, |flexible| by design, |integrated| across capabilities and |selective| about partnerships.
The people advising you are the people doing the work. No layers of junior consultants. We understand the commercial realities behind the strategy. Small by design. Senior by default.
Strategic advice when you need it. Execution when you need more.
Access, commercialization, strategy and growth, connected.
We work with a limited number of clients where we believe we can create meaningful value.
One partner, four ways to engage: |advise|, |partner|, |build|, |lead|.
For strategic questions, assessments and critical decisions. Project-based.
For organizations that need ongoing senior commercial expertise. Strategic partnership.
For launches, market entry and commercialization initiatives. Project plus execution.
For organizations that need experienced leadership without permanent infrastructure. Interim or fractional. That is the difference between advising on commercialization and actually being a commercialization partner.
Where |complexity| and patient need meet most sharply, we build |access| for a narrow |focus|.
Small populations. Specialized stakeholders. Fragmented markets. Complex access pathways. And often, no room for commercial inefficiency.
LUMYNA combines strategic advisory, market access and commercialization expertise to help innovative rare disease therapies reach the patients they were developed for.
Rare diseases. Orphan drugs. Hematology. Oncology. Cell and gene therapy. Specialty pharmaceuticals. Patient access. Early access. Because rare should never mean unreachable.
One continent, thirty commercial realities, where |fragmentation| becomes |opportunity|.
What works in Germany may not work in France. What works in France may not work in Italy. And what works in Italy may need to be completely rethought for the Nordics.
LUMYNA helps clients navigate that complexity with a market-by-market approach, while maintaining one coherent European strategy. One vision. Local intelligence. Connected execution.
We work with |biotech|, |pharma| and |investors|.
You built the science. We help build what comes next. For emerging biotech, building a full European commercial infrastructure can be expensive, slow and difficult to scale. LUMYNA offers another route: senior expertise without unnecessary infrastructure.
Your asset deserves more than a launch plan. Whether entering a new market, repositioning an asset, preparing a launch or transforming a commercial organization, we integrate where complexity is highest.
Commercial insight creates investment insight. Market attractiveness. Competitive dynamics. Pricing and reimbursement. Commercial potential. Launch feasibility. Market-entry requirements. Portfolio opportunities. Growth potential. We don’t just assess the market. We understand what it takes to win in it.
One platform, five capabilities: |advisory|, |gen|, |pharma|, |rare| and |medtech|.
Think. Strategy, assessment, due diligence and commercial leadership.
Expand. Business development, licensing, partnering and international growth.
Launch. Commercialization, market access and operational execution.
Access. Rare disease and specialty medicine commercialization.
Scale. MedTech, diagnostics and digital health commercialization.
Less complexity. More clarity. Better execution.
Built by operators, our |expertise| spans the work and our |execution| is where value is created.
Commercial strategy. Market access. Business development. Licensing. Launches. Commercial operations. International expansion. Rare disease. Oncology and hematology.
We know what happens after the strategy. We know what happens when the market doesn’t behave as expected. And we know that execution is where value is ultimately created. That’s why we stay close to the work.
Perspectives on |approval|, the European |gap|, |rare disease| and hidden |value|.
Beyond Approval. Why regulatory success is only the beginning of commercialization.
The European Commercialization Gap. Why fragmentation creates both risk and opportunity.
Rare Disease, Reimagined. Building sustainable access in underserved markets.
From Asset to Opportunity. How commercial strategy can unlock hidden value.
Innovation deserves |patients|.
But getting there requires more than science. It requires clarity. It requires access. It requires execution. It requires the right partner. From science to market. From market to patients.
Start a conversation
Contact · LinkedIn · Privacy · Legal
© 2026 LUMYNA Pharma